| Overview |
| bs-13954R-Cy3 |
| CILP Polyclonal Antibody, Cy3 Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| The immunogen falls within the Cartilage intermediate layer protein 1 C2 region. |
| Human, Rat |
| Mouse, Cow, Sheep, Horse |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CILP |
| 1051-1184/1184 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 8483 |
| O75339 |
| Cytoplasm |
| CILP-1; HsT18872; Cartilage intermediate layer protein 1; Cartilage intermediate-layer protein; CILP; UNQ602/PRO1188 |
| Probably plays a role in cartilage scaffolding. May act by antagonizing TGF-beta1 (TGFB1) and IGF1 functions. Has the ability to suppress IGF1-induced proliferation and sulfated proteoglycan synthesis, and inhibits ligand-induced IGF1R autophosphorylation. May inhibit TGFB1-mediated induction of cartilage matrix genes via its interaction with TGFB1. Overexpression may lead to impair chondrocyte growth and matrix repair and indirectly promote inorganic pyrophosphate (PPi) supersaturation in aging and osteoarthritis cartilage. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz